etoricoxib

Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

Etoricoxib-D4 is a deuterated form of Etoricoxib. Etoricoxib (T1574) is a synthetic non-steroidal anti-inflammatory compound, an orally available and selective COX-2 inhibitor with antipyretic, analgesic, and potential anticancer properties.

Etoricoxib HCl is a synthetic, nonsteroidal anti-inflammatory drug. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2, resulting in inhibition of the conversion of arachidonic acid into prostaglandins.

Desmethyl etoricoxib (example 21) is a selective COX-2 inhibitor with an IC50 greater than 1 μM in whole blood. It exhibits inhibitory activity against COX-1, with an IC50 of 16 μM in U937 cells, and demonstrates anti-inflammatory properties.

Etoricoxib Impurity 10 is a type of impurity associated with Etoricoxib.

Etoricoxib impurity 17 is an impurity associated with the compound Etoricoxib.

Etoricoxib impurity 2 is a type of impurity associated with Etoricoxib.

Etoricoxib impurity 26 is a byproduct associated with Etoricoxib.

Etoricoxib impurity 7 is an impurity of Etoricoxib.

Etoricoxib (Standard) is the standard substance of Etoricoxib, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

EtoricoxibN1'-oxide is a metabolite of Etoricoxib. It does not inhibit COX-1 and does not significantly inhibit COX-2.